1 stories
AI briefings + tags; source links are the ground truth.
About
🇨🇳
China
South China Morning Post
World
Fosun Pharma’s US$1.55 billion Eisai deal signals shift to long-term partnerships
Fosun Pharma has signed a US$1.55 billion licensing deal with Japan's Eisai for a cancer drug, indicating a trend towards long-term partnerships in the global pharmaceutical industry.
Feb 6 • 09:00 UTC